Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas

Diabetes Care

Volumn 19, Issue 11, 1996, Pages 1185-1189

  Fanghänel, Guillermo ^a,b   Sanchez Reyes, Leticia ^a   Trujillo, Cesar ^a   Sotres, David ^b   Espinosa Campos, Jorge ^b  

^a SECRETARÍA DE SALUD   (Mexico)

^b NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID; METFORMIN; RECOMBINANT HUMAN INSULIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPOTENSION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029905092     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.11.1185     Document Type: Article

References (38)

1. Lozano O, Gonzalez MH, Quibrera R, Garcia VM, Rull J: Tratamiento del diabetico obeso con metformina. Soc Med Nut Endocr (Mex) 8:131-141,1968
2. Fanghânel SG, Esquivel VR, Arauco PR, Monges P, De la Mora C, Villalobos M, Vargas R: Estudio comparativo entre dos meaclas de hipoglucemiantes orales en el tratamiento de la diabetes mellitus de dificil control. Invest Med Int 6: 33-35, 1979
3. Fanghânel SG, Sânchez RL, Trujillo C, Rios JJ, Vargas L, Zûniga S, Quibrera R, Cota J: La combinacion de metforminaglibenclamida en diabeticos tipo II de dificil con falla a la monoterapia. Rev Endocr Nutr (Mex) 3:29-32,1995
4. Bailey CJ: Biguanides and NIDDM. Diabetes Care 15:755-772,1992
5. Hermann LS: Metformin: a review of its pharmacological properties and therapeutic use. Diabetes Metab Rev 5:233-245, 1979
6. Alberti KGMM, Gries FA: Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabetic Med 5:275-281,1988
7. Schafer G: Biguanides: a review of history, pharmacodynamics and therapy. Diabetes Metab Rev 9:148-163, 1983
8. De Fronzo RA, Goodman AM, Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulindependent diabetes mellitus. N Eng! J Med 333:541-549, 1995
9. Nosadini R, Avogaro A, Trevisian R, Valerio A, Tessari P, Duner E, Tkngo A, Velussi M, Del Prato S, De Kreutzenberg S, Moggeo M, Crepaldi G: Effect of metformin on insulin stimulated glucose turnover and insulin binding to receptor in type II diabetes. Diabetes Care 10:62-67,1987
10. Johnson AB, Webster JM, Sum C-F Heseltine L, Argyraki M, Cooper BG, Taylor R: The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 42:1217-1222,1993
11. Widen HIM, ErikssonJG, Groop LC: Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 41:354-358,1992
12. Klip A, Leiter LA: Cellular mechanism of action of metformin. Diabetes Care 13:696-704,1990
13. Dinneen S, Gerich J, Rizza R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N EngI J Med 327:707-713,1992
14. Vigneri R, Goldfine ID: Role of metformin in treatment of diabetes mellitus. Diabetes Care 10:118-122,1987
15. Rolla AR: Resistencia insulinica. Av Diabetol 8:13-36,1994
16. American Diabetes Association: Nutritional recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 17 (Suppl. l):19-22,1994
17. Bhattacharyya GK, Johnson RA: Statistical Concepts and Methods. New York, Wiley, 1987
18. Fleiss JL: The Design and Analysis of Clinical Experiments. New York, Wiley, 1986
19. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
20. DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Cfin Endocrinol Metab 73:1294-1301,1991
21. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB: Acute antihyperglycemic mechanism of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43:920-928, 1994
22. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
23. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Coronary-heart-disease risk and impaired glucose tolerance. Lancet 1:1373-1376,1980
24. Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131-141,1979
25. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diobetologia 19:205-210,1980
26. Welbom TA, Weame K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose end insulin concentrations. Diabetes Care 2:154-160,1979
27. Florey C, Uppal S, Lowy C: Relationship between blood pressure, weight and plasma sugar and serum insulin levels in school-children aged 9-12 years in Westland, Holland. Br J Med 1:1368-1371, 1976
28. Lucas CP, Estigarribia JA, Darga LL: Insulin and blood pressure in obesity. Hypertension 7:701- 706,1985
29. Ferrannini E, Buzzigoli G, Bonadona R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N EnglJMed 317:350-357, 1987
30. Grunfeld B, Balzareti M, Romo M, Gimenez M, Gutman R: Hyperinsulinemia in normotensive offspring of hypertensive patients. Hypertension 23 (Suppl.):l-12, 1994
31. Maheux P,JeppesenJ, Sheu WHH, Hollenbeck CB, Clinkingbeard C, Greenfield MS, Chen Y, Reaven GM: Additive effect of obesity, hypertension and type II diabetes on insulin resistance. Hypertension 24:695-698,1994
32. DeFronzo RA, Ferrannini E: Insulin Resistance: multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194,1991
33. Freidenberg GR, Reichart D, Olefsky JM, Henry RR: Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus: effect of weight loss. J C!in Invest 82:1398-1401,1988
34. Fanhânel G: Acidosis lactica secundaria al uso de biguanidas: ubicacion del problema en Mexico. Rev Med Hasp Gen 51:143-148,1988
35. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP Bleichner G, Chauveau P, Dulbecco P, Guerin C, Haegy JM, Loirat P, Marchand B, Ravaud Y, Weyne P, Foumier A: Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18:779-784,1995
36. Cohen RD: The relative risks of different biguanides in the causation of lactic acidosis. Res C/in Forums 1:125-134, 1979
37. Wiholm BE, Myrhed M: Metformin-associated lactic acidosis in Sweden 1977-1991. Eur ] Clin Pharmacol 44:589-591,1993
38. Campbell IW: Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Supp! 15:105-111, 1985